Following 2019 rejection, FDA adcomm votes against Lexicon's type 1 diabetes and CKD drug
For the second time in five years, an FDA advisory committee voted against endorsing the benefit-risk profile of Lexicon’s drug sotagliflozin.
The Endocrinologic and Metabolic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.